Secondary Outcome(s)
|
Morisky Medication-Taking Adherence Scale (MMAS)
[Time Frame: Up to Week 24]
|
Percentage of participants having SJC <=1
[Time Frame: Up to Week 24]
|
Percentage of participants to achieve a clinically meaningful improvement in DAS28-ESR (reduction of at least 1.2 units)
[Time Frame: Up to Week 24]
|
Time to achieve a clinically meaningful improvement in DAS28-ESR (reduction of at least 1.2 units)
[Time Frame: Up to Week 24]
|
Time to achieve a major and minor improvement in CDAl (>=13.9 and >=6.7, respectively) and SDAI (>=17.1 and >=6.9, respectively)
[Time Frame: Up to Week 24]
|
Percentage of participants using TCZ in monotherapy
[Time Frame: At baseline]
|
EQ-5D-5L Health Questionnaire (EuroQoL)
[Time Frame: Up to Week 24]
|
Change from baseline in total swollen joint count (SJC)
[Time Frame: Up to Week 24]
|
Correlation Coefficient Between CDAI and simplified disease activity index (SDAI) and Between SDAI and DAS28-ESR
[Time Frame: Up to Week 24]
|
Percentage of participants having CRP <=1mg/dl
[Time Frame: Up to Week 24]
|
Percentage of participants having TJC <=1
[Time Frame: Up to Week 24]
|
Percentage of participants to achieve disease remission using DAS28-ESR (<2.6), CDAl (<=2.8) and SDAI (<=3.3)
[Time Frame: Up to Week 24]
|
Change from baseline in total tender joint count (TJC)
[Time Frame: Up to Week 24]
|
Health Assessment Questionnaire Disability Index (HAQ-DI)
[Time Frame: Up to Week 24]
|
Percentage of participants presenting a high inflammation (DAS28-ESR >5.1)
[Time Frame: At baseline]
|
Percentage of participants to achieve low disease activity (LDA) using DAS28 (less than or equal to [<=] 3.2), CDAl (<=10.0) and SDAI (<=11 .0)
[Time Frame: Up to Week 24]
|
Physician Global Assessment of disease activity VAS score
[Time Frame: Up to Week 24]
|
Time to achieve disease remission using DAS28-ESR (<2.6), CDAl (<=2.8) and SDAI (<=3.3)
[Time Frame: Up to Week 24]
|
Time to achieve low disease activity (LDA) using DAS28 (<= 3.2), CDAl (<=10.0) and SDAI (<=11 .0)
[Time Frame: Up to week 24]
|
Percentage of participants using TCZ in combination with disease-modifying antirheumatic drug's (DMARD's)
[Time Frame: At baseline]
|
Patient Global Assessment of disease activity visual analogue scale (VAS) score
[Time Frame: Up to Week 24]
|
Percentage of participants to achieve a major and minor improvement in CDAl (more than or equal to [>=]13.9 and >=6.7, respectively) and SDAI (>=17.1 and >=6.9, respectively)
[Time Frame: Up to Week 24]
|